- Home
- INCY vs YUMC Comparison
INCY vs YUMC Comparison
Compare INCY & YUMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- YUMC
- Stock Information
- Founded
- INCY 1991
- YUMC 1987
- Country
- INCY United States
- YUMC China
- Employees
- INCY N/A
- YUMC 351000
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- YUMC Restaurants
- Sector
- INCY Health Care
- YUMC Consumer Discretionary
- Exchange
- INCY Nasdaq
- YUMC Nasdaq
- Market Cap
- INCY 16.1B
- YUMC 15.6B
- IPO Year
- INCY 1993
- YUMC N/A
- Fundamental
- Price
- INCY $86.85
- YUMC $42.31
- Analyst Decision
- INCY Buy
- YUMC Buy
- Analyst Count
- INCY 20
- YUMC 1
- Target Price
- INCY $80.67
- YUMC $60.00
- AVG Volume (30 Days)
- INCY 1.7M
- YUMC 1.6M
- Earning Date
- INCY 10-28-2025
- YUMC 11-03-2025
- Dividend Yield
- INCY N/A
- YUMC 2.24%
- EPS Growth
- INCY 900.04
- YUMC 16.80
- EPS
- INCY 4.37
- YUMC 2.41
- Revenue
- INCY $4,584,996,000.00
- YUMC $11,434,000,000.00
- Revenue This Year
- INCY $16.36
- YUMC $6.18
- Revenue Next Year
- INCY $10.82
- YUMC $5.92
- P/E Ratio
- INCY $19.80
- YUMC $17.73
- Revenue Growth
- INCY 18.87
- YUMC 3.53
- 52 Week Low
- INCY $53.56
- YUMC $41.00
- 52 Week High
- INCY $88.66
- YUMC $53.99
- Technical
- Relative Strength Index (RSI)
- INCY 59.41
- YUMC 38.47
- Support Level
- INCY $81.09
- YUMC $42.71
- Resistance Level
- INCY $88.66
- YUMC $44.34
- Average True Range (ATR)
- INCY 1.90
- YUMC 0.73
- MACD
- INCY 0.02
- YUMC -0.05
- Stochastic Oscillator
- INCY 76.09
- YUMC 0.92
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About YUMC Yum China Holdings Inc.
With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.